CCL3 Predicts Exceptional Response to TGFβ Inhibition in Basal-Like Pancreatic Cancer Enriched in LIF-Producing Macrophages

Baseline plasma levels of chemokine chemokine ligand 3 (CCL3) were integrated with clinical outcomes in PDAC patients treated with galunisertib plus gemcitabine or placebo plus gemcitabine.